CI-980 in advanced melanoma and hormone refractory prostate cancer

Christopher W. Ryan, Keith L. Shulman, Jon M. Richards, John W. Kugler, Jeffrey A. Sosman, Rafat H. Ansari, Everett E. Vokes, Nicholas J. Vogelzang

    Research output: Contribution to journalArticle

    2 Scopus citations

    Abstract

    Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. Methods: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. Results: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. Conclusions: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.

    Original languageEnglish (US)
    Pages (from-to)187-191
    Number of pages5
    JournalInvestigational New Drugs
    Volume18
    Issue number2
    DOIs
    StatePublished - May 25 2000

    Keywords

    • Chemotherapy
    • Clinical trial
    • Malignant melanoma
    • Prostate cancer

    ASJC Scopus subject areas

    • Oncology
    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'CI-980 in advanced melanoma and hormone refractory prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Ryan, C. W., Shulman, K. L., Richards, J. M., Kugler, J. W., Sosman, J. A., Ansari, R. H., Vokes, E. E., & Vogelzang, N. J. (2000). CI-980 in advanced melanoma and hormone refractory prostate cancer. Investigational New Drugs, 18(2), 187-191. https://doi.org/10.1023/A:1006382014403